You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFerric Carboxymaltose
Accession NumberDB08917
TypeSmall Molecule
GroupsApproved
DescriptionFerric Carboxymaltose is an iron replacement product and chemically, an iron carbohydrate complex. FDA approved on July 25, 2013.
Structure
Thumb
Synonyms
Iron Carboxymaltose
Iron Dextri-Maltose
VIT 45
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
InjectaferInjection, solution50 mg/mLIntravenousAmerican Regent, Inc.2013-08-12Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII6897GXD6OE
CAS number9007-72-1
WeightNot Available
Chemical FormulaNot Available
InChI KeyNot Available
InChINot Available
IUPAC NameNot Available
SMILESNot Available
Pharmacology
IndicationFerric carboxymaltose is a iron replacement product indicated for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron or those who have non-dialysis dependent chronic kidney disease.
Structured Indications
PharmacodynamicsWhen measured using positron emission tomography (PET), the red cell uptake of 59-Fe and 52-Fe from INJECTAFER ranged from 61% to 99%. In patients with iron deficiency, the red cell uptake ranged from 91% to 99%. In patients with renal anemia, the red cell uptake ranged from 61% to 84%.
Mechanism of actionFerric carboxymaltose is a colloidal iron (III) hydroxide in complex with carboxymaltose, a carbohydrate polymer that release iron.
Related Articles
AbsorptionWhen a single dose of 100 to 1000 mg of iron was given to iron deficient patients, the maximum serum concentration (Cmax) was 37 μg/mL to 333 μg/mL. These levels were obtained 15 minutes to 1.21 hours post dose (Tmax).
Volume of distribution

3 L

Protein bindingNot Available
MetabolismNot Available
Route of eliminationRenal elimination of iron was negligible.
Half life7 to 12 hours.
ClearanceNot Available
ToxicityThe most common adverse reactions (>2%) are nausea, hypertension, flushing, hypophosphatemia, and dizziness.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminum phosphateAluminum phosphate can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AsenapineAsenapine can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium carbonateCalcium carbonate can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CefdinirThe serum concentration of Cefdinir can be decreased when it is combined with Ferric Carboxymaltose.Approved
ChlortetracyclineChlortetracycline can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
CimetidineCimetidine can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CinoxacinThe serum concentration of Cinoxacin can be decreased when it is combined with Ferric Carboxymaltose.Approved, Withdrawn
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Ferric Carboxymaltose.Approved, Investigational
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Ferric Carboxymaltose.Approved
DemeclocyclineDemeclocycline can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DimercaprolDimercaprol may increase the nephrotoxic activities of Ferric Carboxymaltose.Approved
Dipotassium phosphateFerric Carboxymaltose can cause a decrease in the absorption of Dipotassium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Ferric Carboxymaltose.Approved
DoxepinDoxepin can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DoxycyclineDoxycycline can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
EltrombopagThe serum concentration of Eltrombopag can be decreased when it is combined with Ferric Carboxymaltose.Approved
EnoxacinThe serum concentration of Enoxacin can be decreased when it is combined with Ferric Carboxymaltose.Approved
EpinastineEpinastine can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
EsomeprazoleEsomeprazole can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
FamotidineFamotidine can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FleroxacinThe serum concentration of Fleroxacin can be decreased when it is combined with Ferric Carboxymaltose.Approved
FlumequineThe serum concentration of Flumequine can be decreased when it is combined with Ferric Carboxymaltose.Withdrawn
GarenoxacinThe serum concentration of Garenoxacin can be decreased when it is combined with Ferric Carboxymaltose.Investigational
GatifloxacinThe serum concentration of Gatifloxacin can be decreased when it is combined with Ferric Carboxymaltose.Approved, Investigational
GemifloxacinThe serum concentration of Gemifloxacin can be decreased when it is combined with Ferric Carboxymaltose.Approved, Investigational
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Ferric Carboxymaltose.Withdrawn
LansoprazoleLansoprazole can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LevodopaThe serum concentration of Levodopa can be decreased when it is combined with Ferric Carboxymaltose.Approved
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Ferric Carboxymaltose.Approved, Investigational
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Ferric Carboxymaltose.Approved
Lipoic AcidFerric Carboxymaltose can cause a decrease in the absorption of Lipoic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Nutraceutical
LomefloxacinThe serum concentration of Lomefloxacin can be decreased when it is combined with Ferric Carboxymaltose.Approved
MagaldrateMagaldrate can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MethanthelineMethantheline can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MethyldopaThe serum concentration of Methyldopa can be decreased when it is combined with Ferric Carboxymaltose.Approved
MetiamideMetiamide can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
MinocyclineMinocycline can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MoxifloxacinThe serum concentration of Moxifloxacin can be decreased when it is combined with Ferric Carboxymaltose.Approved, Investigational
Nalidixic AcidThe serum concentration of Nalidixic Acid can be decreased when it is combined with Ferric Carboxymaltose.Approved
NemonoxacinThe serum concentration of Nemonoxacin can be decreased when it is combined with Ferric Carboxymaltose.Investigational
NizatidineNizatidine can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
NorfloxacinThe serum concentration of Norfloxacin can be decreased when it is combined with Ferric Carboxymaltose.Approved
OfloxacinThe serum concentration of Ofloxacin can be decreased when it is combined with Ferric Carboxymaltose.Approved
OlanzapineOlanzapine can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
OmeprazoleOmeprazole can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
OxytetracyclineOxytetracycline can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PancrelipasePancrelipase can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PantoprazolePantoprazole can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PazufloxacinThe serum concentration of Pazufloxacin can be decreased when it is combined with Ferric Carboxymaltose.Investigational
PefloxacinThe serum concentration of Pefloxacin can be decreased when it is combined with Ferric Carboxymaltose.Approved
PenicillamineFerric Carboxymaltose can cause a decrease in the absorption of Penicillamine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PrulifloxacinThe serum concentration of Prulifloxacin can be decreased when it is combined with Ferric Carboxymaltose.Investigational
RabeprazoleRabeprazole can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
RanitidineRanitidine can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RosoxacinThe serum concentration of Rosoxacin can be decreased when it is combined with Ferric Carboxymaltose.Approved
Roxatidine acetateRoxatidine acetate can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium glycerophosphateFerric Carboxymaltose can cause a decrease in the absorption of Sodium glycerophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium phosphateFerric Carboxymaltose can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Ferric Carboxymaltose.Approved
TAK-390MRTAK-390MR can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
TemafloxacinThe serum concentration of Temafloxacin can be decreased when it is combined with Ferric Carboxymaltose.Withdrawn
TetracyclineTetracycline can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
TriethylenetetramineThe serum concentration of Ferric Carboxymaltose can be decreased when it is combined with Triethylenetetramine.Approved
TrovafloxacinThe serum concentration of Trovafloxacin can be decreased when it is combined with Ferric Carboxymaltose.Approved, Withdrawn
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS Codes
  • 20:04.04
PDB EntriesNot Available
FDA labelDownload (269 KB)
MSDSNot Available
ADMET
Predicted ADMET featuresNot Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Injection, solutionIntravenous50 mg/mL
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7612109 No2004-02-052024-02-05Us
US7754702 No2007-02-132027-02-13Us
US8895612 No2007-01-082027-01-08Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted PropertiesNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Taxonomy
ClassificationNot classified
Comments
comments powered by Disqus
Drug created on July 31, 2013 23:33 / Updated on December 07, 2016 02:39